10
Participants
Start Date
January 30, 2020
Primary Completion Date
December 31, 2025
Study Completion Date
July 29, 2026
Inhaled Treprostinil
"Inhaled treprostinil causes dilatation of the pulmonary arteries and may help reduce the pulmonary pressures in this studied population.~All subjects will initiate inhaled treprostinil at a dose of 3 breaths (18 mcg) four times daily. Study drug doses escalations (additional one breath four times daily) can occur every three days with a maximum dosing regimen of up to 12 breaths (72 mcg) four times daily, as clinically tolerated."
RECRUITING
University of Florida, Division of Pulmonary and Critical Care Medicine, Gainesville
Collaborators (1)
United Therapeutics
INDUSTRY
University of Florida
OTHER